Browse articles from EyeWorld.org related to the retina. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ FDA approves ophthalmic spray for mydriasis
➤ FDA accepts NDA for travoprost intraocular implant
➤ FDA accepts supplemental BLA for treatment for macular edema
➤ FDA 510(k) clearance granted to green pattern laser photocoagulator
➤ NDA submitted for pain and inflammation nanoemulsion
➤ Positive clinical results from IOP-monitoring contact lens
➤ Study provides real-world data comparing MIGS using IRIS Registry
➤ FDA approves IOL positioning system
➤ ASCRS news and events
➤ Topline data from Phase 3 presbyopia drop trial
➤ Femtosecond laser for LASIK receives FDA clearance
➤ Enrollment complete for hydrophobic trifocal IOL trial
➤ Early results from clinical trial for dry eye therapy
➤ FDA clears IND application for clinical trial of therapy for X-linked retinoschisis
➤ Innovations in capsulotomy creation device
➤ Company acquisition news
➤ ASCRS news and events
➤ First in-human, non-invasive femtosecond laser trabeculotomy data
➤ Special Protocol Assessment received for Phase 2b/3 trial for dry AMD treatment
➤ FDA gives clearance to IND for geographic atrophy treatment
➤ Positive preliminary data in trial for retinitis pigmentosa and Leber congenital amaurosis therapy
➤ Wet AMD treatment proceeds to Phase 2 trial
➤ ASCRS news and events
➤ Fast-Track Designation granted for persistent epithelial defect treatment
➤ Study: automated capsulotomy device and white cataracts
➤ Dose escalation complete for Phase 1/2 study evaluating an RP treatment
➤ Companies enter agreement for sustained-release glaucoma treatment
➤ ASCRS news and events
➤ Positive preclinical results for non-viral gene therapy platform
➤ Real-world data confirms efficacy of investigational LHON therapy
➤ Largest genome wide study of photoreceptor cells to date
➤ CDC continues to investigate infectious outbreak associated with artificial tear use
➤ Updates from AAV-based gene therapy program for retinal conditions
➤ ASCRS news and events
➤ Results from investigational non-incisional glaucoma treatment
➤ Study: preservative-free latanoprost efficacy similar to preserved alternative
➤ FDA accepts priority review NDA for vitreoretinal lymphoma treatment
➤ Companies partner to develop dry eye drop
➤ Company announces lead asset in its agonist antibody pipeline
➤ ASCRS news and events
➤ NDA submitted for sustained-release travoprost implant
➤ BLA for wet AMD, DME, DR treatment accepted with priority review
➤ Topline results from 12-month safety clinical trial for investigational dry eye drug
➤ Companies collaborate for research on sustained release for investigational GA drug
➤ ASCRS news and events
➤ First FDA-approved treatment for geographic atrophy
➤ FDA accepts NDA for presbyopia drop
➤ NDA for geographic atrophy drug accepted with priority review
➤ Study: 5-year visual field data with MIGS device
➤ ASCRS news and events
➤ FDA accepts NDA for dry eye treatment
➤ Phase 2 study moves forward for investigational ocular autoimmune therapy
➤ Fast-track designation granted for investigational retinitis pigmentosa treatment
➤ First-in-human feasibility study data from drug-eluting IOL platform
➤ Study identifies the ‘best approach’ for anti-VEGF therapy for diabetic retinopathy
➤ ASCRS news and events
➤ FDA approves treatment for subfoveal choroidal neovascularization due to AMD
➤ IND for inherited RPE clinical trial receives FDA clearance
➤ Phase 3 clinical trial to evaluate cooling device for anesthesia prior to injections
➤ Study calls ‘long-believed theory about diabetic cataracts into question’
➤ ASCRS news and events
